Anemia and Inflammation

NCT ID: NCT03618914

Last Updated: 2018-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-15

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron Deficiency Anemia Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-anemic women

Dultavax and Vaxigrip

Intervention Type BIOLOGICAL

All the women got an influenza/DTP vaccine in order to induce acute inflammation

anemic women

anemia due to iron deficiency

Dultavax and Vaxigrip

Intervention Type BIOLOGICAL

All the women got an influenza/DTP vaccine in order to induce acute inflammation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dultavax and Vaxigrip

All the women got an influenza/DTP vaccine in order to induce acute inflammation

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI \<27.5kg/m2
* body weight \<70kg
* either non-anemic (Hb\>12.5g/dl) or anemic (Hb between 8-12 g/dl and ferritin \<15ng/ml)

Exclusion Criteria

* pregnant or lactating
* chronic disease
* smoking
* inflammation defined as CRP\<5mg/L; AGP\<1g/L
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ibn Tofail University-CNESTEN

UNKNOWN

Sponsor Role collaborator

Swiss Federal Institute of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Michael B. Zimmermann

Prof. Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ibn Tofail University-CNESTEN

Rabat, , Morocco

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Morocco

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMILE Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hepcidin After Intravenous Iron Treatment
NCT06264687 NOT_YET_RECRUITING
Iron Substitution in Blood Donors
NCT01519830 COMPLETED PHASE4
Iron Absorption From Plant Heme Iron
NCT07143890 RECRUITING NA